Plasminogen activation is catalyzed both by tissue-type-(t-PA) and by urokinase-type plasminogen activator (u-PA). This reaction is controlled by plasminogen activator inhibitor type 1 (PAI-1) that is either present in plasma or bound to fibrin, present in a thrombus. We studied the mechanism of in vitro inhibition of both t-PA and u-PA activity by PAI-1 bound to fibrin. It is shown that activation of latent PAI-1 unmasks a specific fibrin-binding site that is distinct from its reactive site. This reactive site of activated PAI-1 bound to fibrin is fully exposed to form complexes with t-PA and u-PA, that are unable to activate plasminogen. Upon complex formation with either one of the plasminogen activators, PAI-1 apparently undergoes a conformational change and loses its affinity for fibrin. Consequently, complexes of u-PA and PAI-1 dissociate from the fibrin matrix and are encountered in the fluid phase. In contrast, t-PA/PAI-1 complexes remain bound to fibrin. By employing recombinant t-PA deletion-mutant proteins, that precisely lack domains involved in fibrin binding, we demonstrate that binding of t-PA/PAI-1 complexes is mediated by both the "finger" (F) and the "kringle-2" (K2) domain of t-PA. A model is proposed that explains inhibition of the fibrinolytic process, at the level of plasminogen activation by t-PA, directed by PAI-1 bound to fibrin. An implication of the proposed model is that t-PA/PAI-1 complexes and free t-PA compete for the same binding sites on fibrin.
Introduction
Limited proteolysis of the zymogen plasminogen and of fibrin by the serine proteases tissue-type plasminogen activator (t-PA)' and plasmin, respectively, forms the basis of the fibri- 1 . Abbreviations used in this paper: a2AP, a2-antiplasmin; del.FEK2, deletion mutant oft-PA, lacking F, E and K2; del.F, deletion mutant of t-PA, lacking F; del.K2, deletion mutant of t-PA, lacking K2; E, epidermal growth factor-like domain; EACA, e-amino caproic acid; F, finger domain; HAT, hypoxanthine, aminopterin, thymidine; H, heavy (chain oft-PA); K 1, kringle-l domain; K2, kringle-2 domain; L, light (chain of t-PA); PAI-1, plasminogen activator inhibitor type 1; t-PA, tissue-type plasminogen activator; u-PA, urokinase-type plasminogen activator. nolytic process (1) . The solid-phase component fibrin plays a pivotal role in this process. First, it provides for a selective binding surface both for t-PA and its substrate plasminogen. The assembly of these three components greatly facilitates the conversion of plasminogen into plagmin (2, 3) . Second, fibrin interacts with serine protease inhibitors (serpins) that restrain the action of either plasmin or t-PA. For instance, it has been shown that a2-antiplasmin (a2AP), a specific inhibitor of plasmin, is bound to fibrin and subsequently crosslinked (4) .
Furthermore, it has recently been reported that plasminogen activator inhibitor type I (PAI-1), a specific inhibitor of both t-PA and u-PA, binds to fibrin, but is apparently not crosslinked (5) . In this paper, we have focussed on the interplay between fibrin, t-PA (or u-PA) and PAI-1, in the absence of plasminogen. A number of structural and biological features of t-PA and PAl- 1 have been reported that are pertinent to this study.
The serine protease t-PA, the predominant plasminogen activator in blood, is synthesized and secreted by endothelial cells and circulates in a single-chain form (6) (7) (8) . This form is cleaved by plasmin into the double-chain form, consisting of an amino-terminal "heavy" (H) chain and a carboxy-terminal "light" (L) chain held together by a disulfide bond (9, 10) . The H chain is composed of distinct structural and functional domains that share homology with other plasma proteins (11, 12) . Starting from the amino terminus, a "finger" domain (F) can be distinguished, followed by an "epidermal growth factor" domain (E), and two "kringle" structures (Kl and K2).
Studies on t-PA deletion mutants revealed the presence of fibrin-binding sites on the F as well as on the K2 domain, the latter representing a lysine-binding site (13, 14) . Recently, it has been indicated that another lysine-binding site, maybe involved in fibrin binding, is located on Kl (15) . The L chain contains the trypsin-like serine protease moiety, that interacts with the substrate plasminogen (16) . It also constitutes the major "target" for the specific plasminogen activator inhibitor PAI-l (17) .
PAI-1 belongs to the serpin family, a large group of proteins, sharing structural features and a common functional principle (18, 19) . Serpins act as ideal pseudosubstrates for their target serine proteases. The serine residue of the active center of the protease reacts with the P1 residue of the reactive site of the serpin. This interaction ultimately results in a scission of the P1-P 1' peptide bond and in a tight linkage between the protease and the P1 residue. As a consequence, a 1:1 molar complex of the serpin and the target protease is formed (18) . In general, serpins can interact with several serine proteases. The physiological role of a serpin and its specificity are, however, determined by the colocalization of a particular serpin and its target protease, their (local) concentration and the affinity of nants together, two serpins appear to be the primary inhibitors of fibrinolysis, a2AP and PAI-1.
Recently, full-length cDNAs of a2AP and PAI-I have been constructed and the nucleotide sequences have been established (20) (21) (22) (23) (24) (25) . The predicted amino-acid sequences clearly pointed out that these proteins are both members of the serpin family. a2AP is synthesized by hepatocytes, whereas the site of synthesis of PAI-I is not clear (26) . At least part of PAI-I in blood is contained within platelets (27) (28) (29) . PAI-1 is also synthesized and secreted by cultured endothelial cells and hepatocytes (30, 31) . Remarkably, in such conditioned media PAI-l is encountered predominantly as an inactive (latent) component. Upon treatment with denaturants [e.g., SDS, guanidine hydrochloride (32)] or with more physiological agents [negatively charged phospholipids (33) ], PAI-1 is activated and, consequently, will inhibit its target proteases t-PA and u-PA. Undoubtedly, PAI-l and a2AP share many important structural and functional features. Nevertheless, in the presence of fibrin their mechanism ofaction may, at least in part, be rather distinct. Upon formation of a fibrin clot, a2AP can be crosslinked to fibrin by Factor XIII and in this way protects the clot from "premature" lysis by plasmin (4, 34) . Concerning the interaction of PAI-1, t-PA (u-PA) and fibrin several observations are relevant in this respect. As mentioned before, it has been shown that PAI-1 is bound to fibrin, but is not crosslinked (5). Furthermore, it has been demonstrated that platelets (in this context present in a clot) activated by thrombin release substantial amounts of PAI-1 (27) . It has been proposed that this event may yield local, high concentrations of PAI-1, inhibiting premature lysis of the clot. In this case, inhibition of lysis would then conceivably occur at the level of plasminogen activation. In this paper, we report on the interaction between fibrin, t-PA (u-PA) and PAI-1 and present a model that differs from equivalent interactions, involving a2AP.
Methods
Materials. Iscove's modified Dulbecco's medium and Ultroser G were from Gibco (Paisley, U.K.). Hypoxanthine, aminopterin and thymidine were purchased from Sigma Chemical Co. (St. Louis, MO). Human plasminogen-free fibrinogen was from IMCO (Stockholm, Sweden) and bovine thrombin was from Hoffmann-La Roche (Basel, Switzerland).
[35S]Methionine was purchased from The Radiochemical Centre (Amersham, U.K.). The murine monoclonal antibody antit-PA L-chain IgG ESP2 was purchased from Bioscot (Edinburgh, UK). The murine monoclonal antibody anti-t-PA L-chain IgM MPWIv-PA and (high-molecular-weight) u-PA were gifts from Dr. B. R. Binder (University of Vienna, Vienna, Austria) and Dr. G. Cassani (Lepetit, Milano, Italy), respectively. The chromogenic substrate H-D-isoleucyl-L-prolyl-L-arginine-p-nitroanilide-dihydrochloride (S2288) to determine the amidolytic activity of t-PA was from KabiVitrum (Stockholm, Sweden). Plasmid pAGO, containing the Herpes simplex virus thymidine kinase gene has been described before (35 Construction of rt-PA deletion mutants. The plasmid pSV2/t-PA, containing full-length human t-PA cDNA (13) , was used to construct the t-PA deletion-mutant cDNAs. To construct the mutant cDNAs a 1417 base pair (bp) fragment of the pSV2/t-PA full-length cDNA, extending from the Hind III site (position 1) to the Sac I site (position 1417) was inserted into the Hind III/Sac I digested polylinker of the double-stranded replicative form of Ml 3mpl8am4 bacteriophage DNA (36) . Subsequently, the "M13 gapped-duplex outlooping" mutagenesis procedure (37) was employed using both recombinant M13mpl8am4 (single-stranded) and M13mpl8 (double-stranded, linearized) and different synthetic oligonucleotides (36-mers) to delete the desired parts ofthe t-PA cDNA (Table I ). It should be noted that none ofthe constructions would ultimately encode a protein with novel free cysteine residues. DNA sequence determinations were performed to verify correct fusion sequences (38). Finally, different mutated fragments were exchanged in the pSV2/t-PA full-length cDNA to obtain the set of t-PA deletion cDNAs under the control of the SV40 early promotor.
Expression ofrt-PA deletion mutants. Mouse Ltk-cells were maintained in Iscove's modified medium, containing penicillin, streptomycin and 10% (vol/vol) FCS. Semiconfluent monolayers of Ltk-cells were exposed for 4 h to a calcium-phosphate co-precipitate (39) ofboth pSV2/t-PA (or variants thereof) and pAGO plasmid DNAs (20 and 1 ,ug, per 80 cm2 flask, respectively). The cells were "shocked" for 2 min with 15% (vol/vol) glycerol. After recovery of the cells for 24-48 h, in medium containing serum, the cells were trypsinized and replated in selective medium containing hypoxanthine (12 Ag/ml), aminopterin (1 ,gg/ml), and thymidine (8 gg/ml) (HAT). After 7 to 14 d, colonies resistant to this selection medium were taken. Separate colonies were grown and incubated for 2-3 d in medium without serum, before samples were collected to test them for rt-PA (variant) production. The clones secreting the highest amount of rt-PA activity were chosen and grown in Iscove's, penicillin, streptomycin, HAT, supplemented with 2% (vol/vol) Ultroser G. Confluent cells were washed with PBS and incubated with "harvest" medium (Iscove's, penicillin, streptomycin, HAT, Trasylol [60 KIE/ml]). Conditioned media were collected after 3 ([35S] PAI-1) were purified from the respective conditioned media using a one-step immunoaffinity-purification procedure. The media were chromatographed at 4°C on the murine monoclonal anti-PAI-I IgG (1C3), immobilized on Sepharose beads. The Sepharose beads were washed with PBS, containing 1 M NaCI, and PAI-l was eluted using 0.1 M glycine (pH 3), supplemented with 0.01% Tween-80. The eluted fractions were collected in 1 M Tris-HCl buffer, pH 7.5 (1/10 of the eluted volume). The homogeneity of the PAI-l preparation was assessed by SDS-polyacrylamide gelelectrophoresis (SDS-PAGE) (43), followed by Coomassie brilliant-blue staining. A single band was visualized of -52,000 Mr. The identity of the purified protein was confirmed by SDS-PAGE, followed by reverse-fibrin autography (44 The half-maximal inhibition of the amidolytic activity of t-PA by PAI-1 preparations was determined, using the chromogenic substrate S2288. Activation was achieved by dialysis for 1 h at room temperature against 6 M guanidine hydrochloride, followed by dialysis against PBS, containing 0.1% (vol/vol) Tween-80. Activated PAI-1 preparations contained -20% active PAI-l. The protein concentration ofpurified PAI-I was determined by amino-acid compositional analysis as described previously (45) . Preparation offibrin matrices. Fibrin matrices were prepared in 24-well tissue-culture plates, essentially as described previously (46) . 200 ,l assay buffer (PBS, 0.01% (vol/vol) Tween-80), containing 1 mg/ml BSA and 1 mg/ml plasminogen-free fibrinogen (except if otherwise stated) were added to each well, and mixed with 2.5-,ul bovine thrombin (100 U/ml) in assay buffer. The plates were left at room temperature for 1 h, subsequently air-dried overnight at 37°C, and stored at 4°C until use. Control plates without fibrinogen were prepared as described above.
Binding of t-PA and u-PA, respectively, tofibrin matrices. 200 Ml assay buffer, containing t-PA (0.15 pmol) or u-PA (0.1 pmol) were incubated for 1 h at 37°C with fibrin matrices. Subsequently, the supernatants were collected and the wells were washed five times with 2 ml assay buffer, containing 10 mg/ml BSA. The wells were then incubated for 1 h at room temperature with 200 ,l assay buffer, containing 1 mg/ml BSA and 1% (wt/vol) SDS. As a consequence, complete lysis of the fibrin matrices occurs. For comparison, the supernatants (in the following referred to as "non-fibrin-binding" fractions) were brought to a final concentration of 1% (wt/vol) SDS as well and incubated for 1 h at room temperature before further use. The SDStreated lysates of the fibrin matrices were diluted in an identical manner as the nonbinding fraction with assay buffer and denoted as "fibrin-binding" fractions. Aliquots of the nonfibrin binding and fibrinbinding fractions were analyzed by SDS-PAGE, followed by fibrin autography (47) . Clear zones in the fibrin overlay indicate plasminogen activator activity and their position allows an estimation of the apparent molecular weights. Experiments in control wells were performed as described above.
Binding ofPAI-I tofibrin matrices. 200 Al of assay buffer, containing latent or activated [35S]PAI-l (10,000 cpm) were applied to the fibrin-binding assay as described above. Nonfibrin binding fractions and fibrin-binding fractions were characterized by SDS-PAGE, followed by reverse fibrin autography. The zones of the SDS-PAGE gels corresponding to the lysis-resistant zones in the fibrin indicator films were quantitatively recovered and counted. Subsequently, the relative distribution of [35S]PAI-1 in the nonfibrin-binding and fibrin-binding fractions was calculated. Additionally, fibrin matrices were prepared following the protocol described above, using fibrinogen at different concentrations (0.04-2.5 mg/ml). Latent and activated [35S]PAI-l (10,000 cpm each), were applied to the fibrin matrices, respectively, and the resulting fibrin-binding fractions were analyzed. Aliquots of the fibrin-binding fractions were counted. The relative amounts of each PAI-I entity (latent or activated), contained in the fibrin-binding fractions were calculated and plotted against the respective fibrin concentrations. Binding to control wells was performed to determine the specificity of the assay for binding of PAI-I to fibrin.
Complex formation of PAI-I bound to fibrin with u-PA, t-PA, or t-PA deletion mutants. The fibrin-binding assay described above was modified as follows: 200 Al assay buffer containing -2 pmol activated PAI-I was incubated for 1 h at 37°C with fibrin matrices. Then, the supernatants were removed and the fibrin matrices washed as outlined before. Subsequently, the fibrin matrices were further incubated for 1 h at 37°C with assay buffer containing 1 mg/ml BSA and either u-PA (0.19 pmol), t-PA (0.15 pmol) or t-PA deletion mutants (del.F, del.K2, and del.FEK2, each 0.15 pmol). Subsequently, non-fibrin-binding and fibrin-binding fractions were obtained as outlined above. Aliquots of each fraction were analyzed by SDS-PAGE followed by fibrin autography.
Binding ofpreformed enzyme/inhibitor complexes to fibrin matrices. Enzyme/inhibitor complexes were formed by incubating t-PA (0.15 pmol), t-PA deletion mutants (del.F, del.K2, del.FEK2, each 0. 15 pmol), or u-PA (0.19 pmol), respectively, for 1 h at room temperature with activated PAI-1 (2 pmol) in assay buffer. Incubation mixtures oft-PA or u-PA, respectively, with PAI-I were then applied to the same fibrin binding assay as described for free t-PA or free u-PA. Non-fibrin-binding and fibrin-binding fractions obtained as above were subjected to SDS-PAGE, followed by fibrin autography. Incubation mixtures oft-PA, del.K2 and del.F, respectively, with PAI-1, were applied to the fibrin-binding assay in the absence or presence of e-amino caproic acid (EACA) (1 mM, 10 mM or 50 mM) during the incubation and the washing steps. Fibrin-binding fractions were obtained and tested by fibrin autography after SDS-PAGE.
Immunoradiometric assay for t-PA L-chain antigen. Monoclonal anti-human L-chain IgM (MPWIv-PA) coupled to Sepharose beads was incubated with cell culture supernatants (containing del.F, del.K2, or del.FEK2), and monoclonal anti-human t-PA L-chain '25I-labeled IgG ESP2 (15,000 cpm) in PBS, containing 10 mg/ml BSA, and 0.1% (vol/vol) Tween-20. Head-over-head rotation of the incubation mixture was performed overnight at room temperature in polystyrene tubes. Then, the Sepharose beads were washed five times with 1.5 ml of 0.15 M NaCl, 0.1% (vol/vol) Tween-20, 10 mM EDTA, and the bound radioactivity was determined. Serial dilutions of Bowes melanoma t-PA were used as standard.
Miscellaneous. SDS-PAGE, fibrin autography and reversed-fibrin autography were performed essentially according to the original protocols (43, 44, 47) . Mapping of the t-PA L-chain-specific monoclonal antibodies anti-t-PA ESP2 and MPWIv-PA, directed against different epitopes, was performed as described previously (48) . Radiolabeling of monoclonal ESP2 was done as described before (48) . The murine monoclonal anti-PAI-I IgG was prepared in the Department of Blood Coagulation of this Institute and has been described previously (49) .
Results
Fibrin-binding assay. A specific fibrin-binding assay has previously been described for Glu-plasminogen (46) . It is based on fibrin generated by thrombin digestion of intact fibrinogen that has subsequently been dehydrated before use. This assay has been employed throughout this study as well and is shown (Fig. 2) Ids to fibrin mg/ml) provides for maximal binding of 0.2 nM of PAI-1, this experi-either activated or nonactivated. Moreover, the optimal bindoe associated ing and the relative efficiency of both PAI-i species correibrin nor to sponds with the data presented in Fig. 2 . ,ific binding Complexformation ofPAI-I bound tofibrin with t-PA and no binding u-PA. Several reports have shown that t-PA-(or u-PA) activity can be recovered in situ from 1:1 molar complexes with PAI-1 the extent of after treatment with SDS and Triton X-100 (50, 51). This s was subse-observation forms the basis of the following experiments. Aca homoge-tivated PAI-1 was bound to fibrin matrices that were subsered, human labeled with Lion were ei- Figure 3 . quently washed and then incubated with either tThe reaction mixture was analyzed by fibrin autc respect to free plasminogen activator (PA) activit activity complexed with PAI-1, either bound to fi bound. The data, presented in Fig. 4 , demonstra plasminogen activators indeed form complexes wi tially bound to fibrin. Complexes of t-PA or u-PA migrated at apparent Mr positions of -120,000 a respectively, as expected from the sum ofthe appa molecular masses of t-PA (69,000) or free u-PA ( PAI-1 (52,000). The extent of complex formati t-PA and u-PA differs: part of t-PA remains uI whereas u-PA is entirely contained within com observation has also been made in the absence off not shown) and may reflect partial dissociation PAI-I complex during electrophoresis, in con u-PA/PAI-I complex. However, we found a signi ence between the interaction of t-PA with PAIT fibrin and that ofu-PA. Upon addition oft-PA to I to fibrin, t-PA/PAI-1 complexes are encountei bound to fibrin, whereas after addition of u-PA thi 1 complexes are detected exclusively in the non tion.
As a control, we verified that the plasminoge indeed interact with PAI-I bound to fibrin and with PAI-I dissociating from the matrix during t bation with the enzymes. Accordingly, PAI-I boi was exposed for the same period to buffer withou sequently, the supematant was incubated with ulyzed by fibrin autography. As anticipated, only fi detected and no PA/PAI-I complexes (Fig. 4, lan trast, addition of u-PA to PAI-I bound to fibrin after the incubation with buffer resulted in the formation of complexes (Fig.  4, lane 6 Domains on t-PA that enable t-PA/PAI-I complexes to in-)graphy with teract withfibrin. Previously, we have demonstrated that bindty and to PA ing oft-PA to forming fibrin is mediated by both the finger (F) ibrin or non-domain and the kringle-K2 domain (13) . Recently, it has been Lte that both indicated that the kringle-KI domain would also be implicated th PAI-I ini-in fibrin binding (15) . With respect to the involvement ofthese L with PAI-I three different domains of free t-PA on the interaction with Lnd 100,000, fibrin, we employed the following mutants: del.F, del.K2 and Lrent relative del.FEK2 (i.e., containing KI). The effect of these mutants on (54,000) and complex formation with PAI-1, prebound to fibrin, was anaion between lyzed essentially as described in the previous paragraphs ncomplexed, (Fig. 6 ). Clearly, all three t-PA mutant proteins forme with PAI-l bound to fibrin. Complexes betwee del.K2 with PAI-I were found to be associated w contrast to complexes with del.FEK2 that were de sively in the nonbound fraction. Hence, the effe( del.FEK2, lacking both F and K2 but retaining K bound to fibrin is similar to that ofu-PA. The sam4 can be drawn for the absence ofbinding ofdel.FEI to fibrin that had not been exposed to PAI-I shown). On the other hand, the effect of the mutai del.K2, lacking either only F or only K2, on PA] fibrin is comparable to that of the complete tThese results indicate that PAI-I loses its affinity i only when complexed with u-PA, but also upor with t-PA. Subsequently, t-PA/PAI-1 complexes r the matrix are rebound to fibrin, mediated by bo the K2 domain in accord with binding of free t- (13) . At least in this assay system, and employing 1 mutants, a contribution of the KI domain of t-P binding is not detectable.
On the nature ofF-and K2-mediated binding 1 complexes to fibrin. We have shown before tha free t-PA to forming fibrin, mediated by the K2 ( be prevented by the lysine analogue EACA (14). binding mediated by the F domain is not affected is conceivable that binding of t-PA/PAI-1 comple mediated as well by the F and K2 domains, is EACA similarly to free t-PA. This expectation was determining the effect of EACA on the interac formed t-PA (mutant)/PAI-1 complexes with fib] purpose, we employed t-PA, del.K2 and del.F, incubated preformed complexes with fibrin in the increasing concentrations of EACA and analyzed that was bound to fibrin (Fig. 7) vitro cultures of these cell types synthesize and secrete PAI-1 (30, 31) . The second pool of PAI-1 in blood is contained within the a-granules of platelets (27) and, most probably, is d complexes synthesized in megakaryocytes. These two separate pools may n delF and serve different functions. The plasma pool, having a concen-'ith fibrin, in tration usually in excess over that of t-PA, inhibits t-PA in the tected exclu-fluid phase by the formation of inactive t-PA/PAI-1 comct of mutant plexes. By this mechanism the generation of plasmin in the A, on PAI-1 circulation is efficiently prevented. The pool of platelet PAI-1 e conclusion may serve a different function, related to the presence of plate-K2 and u-PA lets within a thrombus. Upon activation with specific stimuli (results not (e.g. thrombin), platelets can release PAI-1 (27 Figure 7 . Influence of EACA on the binding of preformed complexes of t-PA or mutants thereof and PAI-I to fibrin matrices. Activated PAI-1 (2 pmol) was incubated for 1 h at 37°C with t-PA (A), del.K2 (B), or del.F (C), before addition to the fibrin matrices. The incubation with fibrin as well as the subsequent washing step was performed in the absence or presence of EACA. The respective fibrinbinding fractions were collected and subjected to fibrin autography after SDS-PAGE. relevance (18) . Thus, the platelet pool may function as the primary local source of PAI-1 in the initial stage of hemostasis and would contribute to stabilization of a (provisional) hemostatic plug by preventing the local action of fibrin-bound t-PA. This view is supported by the recent finding that PAI-1 binds to fibrin, apparently independent of the crosslinking enzyme Factor XIII, and that the fibrin-bound conformation of PAI-1 is able to inhibit t-PA activity (5). Furthermore, it has been reported that platelets contain and release both active and latent PAI-1 (29) . Interestingly, negatively charged phospholipids, that are also released from activated platelets and play a key role in the activation of coagulation factors, can activate latent PAI-1 as well (33) . Hence, these phospholipids might be particularly involved in the activation of the latent fraction of platelet PAI-1 after release into the hemostatic plug. In conclusion, a number of observations have indicated that PAI-1 may inhibit the fibrinolytic system by different pathways, involving either free PAI-1 or PAI-l immobilized on fibrin.
In this paper, we have investigated the mechanism of inhibition of t-PA activity by fibrin-bound PAI-1 in the absence of additional fibrinolytic components. To that end, a specific binding assay for PAI-1 to fibrin was developed. Using this assay, it is revealed that activated PAI-1 binds to a larger extent than latent PAI-1. Activation of latent PAI-1 obviously not only results in exposure of the reactive site for the interaction with its target serine proteases, but also substantially unmasks its fibrin-binding site. We subsequently have compared the effect of t-PA on activated PAI-1 bound to fibrin with that of u-PA and of t-PA deletion mutant proteins, lacking specific structural and functional domains located on the amino-terminal H chain. All plasminogen activators contain an intact catalytic center, located on their respective carboxy-terminal chains, that would be available for an interaction with the reactive site of PAI-1. From our data, it is evident that the reactive site of PAI-1 is not directly involved in binding to the fibrin matrix, since after binding it is fully available for the formation of complexes with any of the plasminogen activators employed.
Taking our results together, a model can be formulated for the interaction of t-PA with activated PAI-1 bound to fibrin that is composed of three sequential steps: (a) The catalytic center of t-PA interacts with the reactive center of PAI-1, bound to fibrin, resulting in a stable complex. The preferential binding of t-PA to PAI-1, instead of binding to fibrin, is in accord with the kinetic parameters reported for these interactions with the separate components (52, 53) . (b) Upon formation of a stable complex with t-PA, PAI-1 apparently undergoes a conformational change and loses its affinity for fibrin. (c) The 1: 1 molar complex of t-PA and PAI-1 dissociates from the fibrin matrix and subsequently rebinds to fibrin. This fibrin binding is dependent on the presence of the finger (F) and/or the kringle-2 (K2) domain of t-PA and is independent of the PAI-1 moiety of the complex.
Actually, at this point we cannot distinguish whether the t-PA/PAI- 1 (55) , that different observations may be due to the use of different assay systems, including other fibrin preparations, and/or differently composed mutant proteins.
Apart from inhibition of fibrinolysis at the level of plasminogen activation by PAI-1, this process is also controlled at the level of plasmin activity by a2AP (4, 34) . As outlined before, both inhibitors (serpins) form a 1:1 molar complex with their respective target proteases and exhibit a significant structural homology. Similar to the action of PAI-1, a2AP also displays two modes of inhibition, i.e., in the fluid phase and crosslinked to fibrin. However, in the latter case, the mechanism of inhibition is clearly distinct from that of PAI-1 bound to fibrin. First, complexes of a2AP/plasmin are associated with fibrin by the a2AP moiety, crosslinked to the matrix. In contrast, we have shown here that PAI-1/t-PA complexes are bound, mediated by the t-PA part. Second, the binding sites for the a2AP/plasmin complex are distinct from those of plasmin, whereas identical binding sites are proposed in this report for free t-PA and for the PAI-l/t-PA complex, based on the F and the K2 domain of t-PA. At present, the physiological significance of the apparently distinct mechanisms of these fibrin-associated inhibitors is not resolved.
The mechanism proposed above offers an explanation for the inhibition ofthe fibrinolytic system, catalyzed by t-PA, due to PAI-1 bound to fibrin. Essential for this explanation is our finding that the fibrinolytically inactive complex of t-PA and PAI-1 still displays fibrin-binding properties. The structural entities of the complex that enable binding, i.e. the F and K2 domains oft-PA, are identical to those of free t-PA. Hence, it is likely that complexes oft-PA/PAI-1 and free t-PA compete for the same binding sites on fibrin and, consequently, complexes will inhibit fibrinolysis by preventing t-PA binding to fibrin, an event that would greatly augment t-PA activity. In conclusion, our results demonstrate that, besides inhibiting t-PA activity in the fluid phase, PAI-1 bound to fibrin can also effectively inhibit t-PA: a mode of action is proposed that ultimately results in the formation of t-PA/PAI-1 complexes that are able to occupy the fibrin-binding sites of free t-PA.
